Canon announced that it established Canon BioMedical, a wholly owned biomedical business to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform.
Canon U.S.A announced on March 2, 2015 that it established Canon BioMedical to develop, manufacture, and market operations related to Canon’s life-science and molecular diagnostics platform. The company also plans to expand the use of Canon technology into other medical fields. Long-term growth includes untapped markets for Canon such as life science, healthcare, and medical analysis through the use of existing and future Canon technologies, as well as partnerships.
"We are truly excited and proud to launch Canon BioMedical, Inc., an American-born worldwide headquarters committed to bringing to market innovative technologies and solutions," said Joe Adachi, chairman and CEO, Canon U.S.A., Inc., in a press release. "We look forward to bringing Canon technology to clinicians and scientists all over the world in an effort to assist in improving human health and in advancing science."
Source: Canon
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.